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Ischemia reperfusionrisk factors of metabolic syndrome culminates in the development of Ischemic
Heart Disease (IHD). Reﬁned diets that lack micronutrients, mainly trivalent chromium (Cr3+) have been
identiﬁed as the contributor in the rising incidence of diabetes. We investigated the effect of niacin-bound
chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats. Rats were
randomized into: Control (Con); Diabetic (Dia) and Diabetic rats fed with NBC (Dia+NBC). After 30 days of
treatment, the isolated hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion.
NBC treatment demonstrated signiﬁcant increase in left ventricular functions and signiﬁcant reduction in
infarct size and cardiomyocyte apoptosis in Dia+NBC compared with Dia. Increased Glut-4 translocation to
the lipid raft fractions was also observed in Dia+NBC compared to Dia. Reduced Cav-1 and increased Cav-3
expression along with phosphorylation of Akt, eNOS and AMPK might have resulted in increased Glut-4
translocation in Dia+NBC. Our results indicate that the cardioprotective effect of NBC is mediated by
increased activation of AMPK, Akt and eNOS resulting in increased translocation of Glut-4 to the caveolar raft
fractions thereby alleviating the effects of IR injury in the diabetic myocardium.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The incidence of diabetes is associated with various risk factors
such as obesity, increasing age, physical inactivity, autoimmune
diseases, pancreatitis, viral infections etc. In addition to these risk
factors, certain nutritional deﬁciencies have also been associated with
a higher incidence of diabetes [1]. Chromium deﬁciency has been
associated with elevated blood glucose levels and diabetes [1].
Chromium (Cr) is an essential micronutrient that is required for
normal carbohydrate and lipid metabolism [1]. Highly reﬁned diets
that may be deﬁcient in micronutrients, mainly trivalent chromium
(Cr3+) have been identiﬁed as the dominant factor in the rising
incidence of diabetes. However, the exact mechanism by which Cr3+
plays an important role in the regulation of glucose metabolism
remains elusive. Furthermore, Cr3+ seems to have a role in increasing
the tyrosine kinase activity of the insulin receptor [2–5]. Different
forms of trivalent chromium such as chromium chloride (CrCl3) and
chromium picolinate have been studied with respect to Type II1 860 679 2825.
ik).
l rights reserved.diabetes or Non-Insulin Dependent Diabetes Mellitus (NIDDM)
but not Type I diabetes or Insulin Dependent Diabetes Mellitus
(IDDM) [5–7]. In addition, Trueblood et al. has shown that niacin
protects the isolated heart from ischemia-reperfusion injury [8] by
lowering the cytosolic redox state and increasing the lactate efﬂux
rate, consistent with redox regulation of glycolysis.
The regulation of glucose uptake and its utilization is critical for the
maintenance of glucose homeostasis. Insulin plays a signiﬁcant role in
controlling the rates of glucose uptake, glycogen synthesis and
glycolysis in the cardiac muscle. It is well established that glucose
uptake is regulated by glucose transporter (Glut-4) in the plasma
membrane [9]. It has been reported that increased glucose uptake in
ischemic cardiomyocytes is achieved primarily by the translocation of
Glut-4 from its intracellular compartments to the caveolae of the
plasma membrane [10–12]. The caveolae are small ﬂask shaped
invaginations (50–100 nm in diameter) which act as the membrane
organizing centers and signaling microdomains of the plasma
membrane in almost all cell types, predominantly in the endothelial
cells, myocytes and the adipocytes [10,13–16]. The structural proteins
(the caveolins, Cav-1, Cav-2, Cav-3), sphingolipids and cholesterol are
the main components of the caveolae [13]. These structural proteins
serve as scaffolds and regulators of many proteins [16]. The M-
Fig. 1. Effect of NBC on blood glucose levels. ⁎pb0.05 compared with control.
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endothelial cells [17,18]. Studies in Cav-3−/− mice have shown that the
absence of caveolin-3 leads to insulin resistance and increased
adiposity [19]. It has also been reported that caveolin-1 acts like a
physiological inhibitor of eNOS and that Cav-1 expression is
upregulated in diabetic NOD mice [20]. eNOS derived NO is key
enhancer of vascular functions, vessel relaxation and survival of
vascular endothelial cells. The phosphorylation of eNOS at Ser1177 is
said to render more activity to the protein. It is demonstrated that Akt/
PKB phosphorylates eNOS at Ser1177 [21]. However, dominant
negative Akt mutants were unable to block the phosphorylation of
eNOS thereby showing an alternative mechanism for the activation of
eNOS [22]. In this context, AMP-activated protein kinase (AMPK) has
been shown to be involved in eNOS activation by enhancing its
phosphorylation [23,24]. AMPK, a serine threonine kinase is known to
be the metabolic master switch that senses and regulates the cellular
energy status in various cell types [24,25]. Furthermore, phosphoryla-
tion of AMPK (pAMPK) and thus its activation has been associated
with increased Glut-4 translocation and therefore increased glucose
uptake in the myocardium [26,27]. We have demonstrated earlier that
redox regulation of ischemic preconditioning is by differential
activation of caveolin-1 and caveoin-3 and their association with
eNOS and Glut-4 in which AMPK is also involved [10].
In conjunction with the previous reports including ours, in this
study we investigated the effect of niacin-bound chromium (NBC)
(commercially known as ChromeMateR) against ischemia/reperfusion
(IR) injury in streptozotocin induced diabetic rats. We also investi-
gated the effect of NBC on the activation of Akt, AMPK and eNOS and
its role in the regulation of Glut-4 translocation to the membrane by
modulating the levels of Cav-1 and Cav-3, in the diabetic myocardium.
2. Materials and methods
2.1. Animals
This study was performed in accordance with the principles of
laboratory animal care formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory Animals
prepared by the National Academy of Sciences and published by the
National Institutes of Health (Publication No. 85-23, revised 1985). The
experimental protocol was examined and approved by the Institu-
tional Animal Care Committee of the Connecticut Health Center
(Farmington, CT). All animals used in the study received humane care
and treatment. Male Sprague Dawley rats (275–300 g) were used for
the study. Experimental diabetes was induced in the animals by a one
time intraperitoneal administration of streptozocin (STZ; Sigma, St
Louis, MO) at a dosage of 65 mg kg−1 in saline. Control rats received an
equal volume of normal saline (i.p). Blood was drawn from the rats by
tail snip, ﬁve days after STZ injection, and blood glucose levels were
measured using glucose monitoring system (Thera Sense, Inc.
Alameda, CA, USA). Rats with blood glucose concentrations
≥300 mg/dl were considered to be diabetic.
2.2. Experimental protocol
Rats were randomly divided into 3 groups (n=24 in each group): 1)
Non-diabetic control rats (Con); 2)Diabetic rats (Dia); 3)Diabetic rats fed
with diet containing Niacin-Bound Chromium (NBC) (Dia+NBC). Niacin
boundchromium III complexcommercially knownasChromeMateRwas
obtained from Inter Health Nutraceuticals. Benecia, CA, USA. The
chromiumdosage for an adultweighing70 kg is 4mg. For a ratweighing
250–275 g it is 0.0145 mg and considering a 5 fold faster metabolism in
the case of rat [28] the daily chromium dose will be 5 times more i.e.
0.0727 mg (we calculated approximately as 0.1 mg due to the body
weight changes during the treatment period of 30days). A 250–275g rat
approximately consumes 25 g of chow/day; hence 4 mg of chromium(0.1/25×1000 g) was mixed with 1 kg of rat chow. After the treatment
period of 30 days, rats were anesthetized; hearts were isolated and
subjected to 30 min of ischemia followed by 2 h of reperfusion.
2.3. Isolated working heart preparation
Rats were given an intraperitoneal bolus of heparin (500 IU kg−1)
and were anesthetized by the intraperitoneal administration of
pentobarbital sodium (80 mg kg−1, Abbot, Baxter Health Care, Deep
Field, IL). After ensuring a sufﬁcient depth of anesthesia, a thoractomy
was performed; the hearts were rapidly excised and transferred into
container having chilled Krebs Henseleit Bicarbonate perfusion Buffer
(KHB, 118 mM NaCl, 4.7 mM KCl, 1.7 mM CaCl2, 25 mM NaHCO3,
1.2 mM KH2PO4, 1.2 mM MgSO4, 10 mM glucose). The aorta was
cannulated, the hearts were subjected to retrograde perfusion on a
Langendorff perfusion system at a hydrostatic pressure of 100 cm of
H2Owhere the buffer was continuously oxygenated andmaintained at
a constant temperature of 37 °C [29,30]. The pulmonary vein was
cannulated to another cannula to continue with the isolated working
heart procedure. The Langendorff preparation was switched to the
antegrade working mode, following a brief washout period, by
switching the supply of the perfusate (maintained at a hydrostatic
pressure of 17 cm of H2O) from the aorta to the left atrium. After the
attainment of steady state, cardiac baseline functional parameters
were recorded. The circuit was then switched back to the retrograde
mode and the hearts were perfused for 5 min with KHB buffer, and
were then subjected to 30 min of global ischemia followed by 2 h of
reperfusion in antegrade working heart mode and the functional
parameters were recorded at 30, 60, 90 and 120 min of reperfusion
[29,30].
2.4. Cardiac function
Aortic pressure was measured using a pressure transducer (Micro-
Med, Inc.,) and the signal was ampliﬁed using a HPA-400 (Micro-Med,
Inc, USA). The Heart Rate (HR), Left Ventricular Developed Pressure
(LVDP), and (dp/dtmax) were all derived from the continuously
obtained pressure signal. Aortic ﬂow (AF) was measured using a
calibrated ﬂow meter (Gilmont Instrument Inc., Barrington, IL, USA)
and coronary ﬂow (CF) was measured by timed collection of the
coronary efﬂuent dripping from the heart [29,30].
2.5. Measurement of infarct
At the end of reperfusion, the heart was perfused with a 1% (w/v)
solution of triphenyl tetrazolium chloride in phosphate buffer through
the aortic cannula for 1min at 37 °C. To quantify the areas of interest in
pixels, Scion image analysis software was used. The infarct size was
quantiﬁed and was expressed in percentage [29,30].
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The formaldehyde-ﬁxed left ventricle was embedded in parafﬁn
and were cut into transverse sections (4 μm thick) and deparafﬁnized
with a graded series of histoclear and ethanol solutions. Immunohis-
tochemical detection of apoptotic cells was carried out using TUNEL
reaction using In Situ Cell Death Detection Kit, Fluorescein as per the
kit protocol (Roche Diagnostics, Mannheim, Germany). In brief, the
TUNEL reaction preferentially labels DNA strand breaks generated
during apoptosis which can be identiﬁed by labeling free 3′-OHFig. 2. Effect of NBC on cardiac functional parameters at baseline (BL) and after 30 min of is
represents dp/dtmax, (C) represents heart rate, (D) represents aortic ﬂow, (E) represents coro
#pb0.05 compared with Diabetic group. Where white bar represents Control, diagonal linetermini with modiﬁed nucleotides in an enzymatic reaction catalysed
by Terminal deoxynucleotidyl transferase (TdT). Fluorescein labels
incorporated in nucleotide polymers are detected by ﬂuorescence
microscopy. The sections (n=5) were washed thrice in PBS, blocked
with 10% normal goat serum in 1% BSA in PBS and incubated with
mousemonoclonal anti-α-sarcomeric actin (Sigma, St Louis, MO, USA)
followed by staining with TRITC-conjugated rabbit anti-mouse IgG
(1:200 dilution, Sigma, St Louis, MO, USA). After incubation, the
sections were rinsed thrice in PBS and mounted with Vectashield
mounting medium (Vector, Burlingame, CA). The sections werechemia at 30, 60, 90 and 120 min of reperfusion. The results in (A) represent LVDP, (B)
nary ﬂow. Results are shown in six animals per group. ⁎pb0.05 compared with control,
bar represent diabetic group and black bar represents Dia+NBC group.
Fig. 3. (A) Graph represents the infarct size between the comparative groups. (B) Graph represents the number of apoptotic cardiomyocytes between the comparative groups.
⁎pb0.05 compared with control and †pb0.05 compared with diabetic group. (C) Figures represent apoptotic cells identiﬁed with anti α-sarcomeric actin speciﬁc for cardiomyocytes.
I–III represent the control group, IV–VI represent the diabetic group and VII–IX represent the Diabetic+NBC group. The white arrows represent the apoptotic cardiomyocytes stained
by TUNEL assay. (D) The representative pictures for quantitative measurement of apoptotic cardiomyocytes using the Metamorph software.
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410 microscope. For the quantitative purpose, the number of TUNEL-
positive cardiomyocytes was counted on 100 high power ﬁelds
(HPF) [29].
2.7. Isolation of caveolin-rich (lipid raft) fractions
100mgof tissuewashomogenized in2mlof sucrosebuffer (250mM
sucrose, 25mMTris (pH 7.4), 2mMEDTA,150mMNaCl,1% TritonX-100,
and protease inhibitor cocktail) according to themodiﬁed protocol of Liu
et al. [31] using a Polytron homogenizer as described by Koneru S et al.
[10]. Sucrose gradientswere prepared (5%, 30%, and 80%) inTNE (25mM
Tris HCl pH 7.5,150mMNaCl,1 mMEGTA) buffer. The lysatewas passed
through a 23-gauge needle, and was then sonicated. Following
sonication, 2 ml of 80% sucrose was added and mixed to make the
sucrose concentration to 40% (1:1 dilution). On the top of this, 4 ml of
30% sucrose was layered, followed by 4 ml of 5% sucrose solution (total
volume=12ml). The tubes containing sucrosegradientwere centrifuged
at 33,000 rpm for 17 h. Following centrifugation, the gradient was
separated into 12 fractions of 1 ml each. The fractions 4–6 were
considered as the lipid raft fractions and the fractions 8–12 were
considered as theheavier fractions. Equal amount of tissue (100mg)was
used for all the groups, and the protein was estimated after isolation of
the fractions. Equal amount of protein was loaded for all the groups to
performwestern blot analysis.2.8. Isolation of cytosolic proteins
Left ventricular tissues from each group were homogenized and
suspended (70 mg/ml) in sample buffer [10 mM HEPES, pH 7.3,
sucrose 11.5%, EDTA 1 mM, EGTA 1 mM, diisopropylﬂuorophosphate
(DFP), pepstatin A 0.7 mg/ml, leupeptin 10mg/ml, aprotinin 2 mg/ml].
The homogenates were centrifuged at 3,000 rpm and the supernatant
was collected and again centrifuged at 10,000 rpm for the cytosolic
fraction. The total protein concentration was determined using BCA
(bicinchoninic acid) protein assay kit (Pierce, Rockville, IL) [29].
2.9. Immunoprecipitation for Cav-1/eNOS and
Cav-3/GLUT-4 association
To observe the association of Cav-1/eNOS and Cav-3/Glut-4 in
the lipid raft fractions immunoprecipitation was performed in
caveolin-rich fractions (fractions 4–6). Immunoprecipitation was
performed with protein-A and protein-G Sepharose beads from
Amersham Biosciences (Piscataway, NJ) using a polyclonal antibody
against Cav-1 and Cav-3 monoclonal antibody from Santa Cruz
Biotechnology (Santa Cruz, CA). The procedure was carried out
according to the manufacturer's protocol. The caveolin-rich frac-
tions (fractions 4–6) were immunoprecipitated with Cav-1 and
Cav-3, which were reblotted with eNOS and Glut-4, respectively
[10].
Fig. 4. (A) Represents the caveolin-1 protein expression in sucrose gradient fractions. (B) Represents the quantitative estimation of caveolin-1 both in the lipid raft fractions (4–6) fractions as well as heavier (8–12) fractions. (C) Represents the
caveolin-3 protein expression in sucrose gradient fractions. (D) Represents the quantitative estimation of caveolin-3 both in the lipid raft fractions (4–6) fractions as well as heavier (8–12) fractions. (E) Represents the Glut-4 protein expression
in sucrose gradient fractions. (F) Represents the quantitative estimation of Glut-4 both in the lipid raft fractions (4–6) fractions as well as heavier (8–12) fractions. ⁎pb0.05 represents the signiﬁcant difference between control and diabetic
group. †pb0.05 represents signiﬁcant difference between diabetic and NBC treated diabetic group.
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Fig. 5. (A) Immunoprecipitation with caveolin-1 and reblot with eNOS in control, Dia
and Dia+NBC groups. (B) Immunoprecipitation with caveolin-3 and reblot with Glut-4
in control, Dia and Dia+NBC groups. n=6 in each group. ⁎pb0.05 represents the
signiﬁcant difference between control and diabetic group. †pb0.05 represents
signiﬁcant difference between diabetic and NBC treated diabetic group.
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p-eNOS, eNOS, p-Akt and Akt
To quantify the expression of Cav-1, Cav-3, Glut-4 in lipid raft
fractions p-eNOS, eNOS, p-Akt, Akt, p-AMPK and AMPK in the
cytosolic fraction, standard SDS-PAGE Western blot analysis was
performed with the use of polyacrylamide electrophoretic gels (7%,
10%, and 12%; acrylamide-to-bis ratios depending on the molecular
weight of the proteins) as described previously [10,29].The antibodies
were purchased (Cell Signaling Technology, Danvers, MA; Abcam,
Cambridge, MA; and Santa Cruz Biotechnology, Santa Cruz, CA) and
were used at manufacturer-recommended dilutions.
2.11. Immunohistochemistry of Caveolin-1/eNOS and Caveolin-3/Glut-4
Parafﬁn embedded tissue sections of 4 μm thick were used for
immunohistochemical analysis. The sections were deparafﬁnized
using histoclear solution, 100% ethanol, 90% ethanol, 80% ethanol
and 70% ethanol followed by Phosphate Buffered Saline (PBS) wash.
Each step was carried for 5 min. Slides were placed in boiling antigen
retrieval buffer for 15 min and was then allowed to cool at room
temperature for 20 min. Again, the slides were rinsed in PBS. The
sections were rinsed with 0.5% BSA in PBS for 20 min. The slides were
blocked in 10% normal donkey serum with 1%BSA in PBS for 2 h. For
Glut-4 the sections were rinsed and blocked with 0.4% triton-X 100
along with BSA. After blocking the sections was incubated overnight
with primary antibodies for Cav-1 (Santa Cruz Biotechnology) Cav-3,
eNOS (BD Pharmingen, San Diego, CA) and Glut-4 (Chemicon
International, Temecula, CA) diluted with 1% BSA in PBS overnight at
room temperature. All primary antibodies were diluted at 1:100 ratios.
After overnight incubation the sections were washed in PBS. The
sections were rinsed with 0.5% BSA in PBS for 3 times for 5 min each.
The sections were incubated with secondary antibodies Alexa ﬂour
555 anti-rabbit (for Cav-1), anti-goat (for Glut-4) and Alexa ﬂour 488
anti-mouse (for Cav-3 and eNOS) from Invitrogen, Eugene, Oregon,
USA. The secondary antibodies were diluted with 1% BSA in PBS. The
sections were incubated in secondary for 2 h. After incubation the
sections were rinsed in PBS and mounted with citiﬂuor mounting
medium (Vector Laboratories Inc, Burlingame, CA 94010). The sections
were observed and pictures were taken using Confocal 410 micro-
scope [10].
2.12. Statistical analysis
Results are expressed as mean±standard deviation of the mean
(±SD). ANOVA followed by Bonferroni's correction was carried out to
determine any differences between the mean values of all groups. The
results were considered signiﬁcant if pb0.05.
3. Results
3.1. Effect of NBC on the glucose level
Blood glucose levels were signiﬁcantly increased in the diabetic
rats when compared to non-diabetic rats. Treatment with NBC
decreased the blood glucose level in Dia+NBC group as compared to
Dia group (Fig. 1) however signiﬁcant difference was not found
between the groups.
3.2. Effect of NBC on cardiac functions
Signiﬁcant reduction in the cardiac functional parameters such as
LVDP (mm Hg), dp/dtmax (mm Hg/s), coronary ﬂow (ml/min), and
aortic ﬂow (ml/min) except for the heart rate (beats/min) was
observed in the diabetic group as compared to the control group at
the baseline as well as during the 2 h of reperfusion.The baseline abnormalities in heart function in STZ-diabetic
myocardium may be due to the production of reactive oxygen
species. However upon NBC treatment there was signiﬁcant
improvement of the cardiac functions at the baseline levels as
well as during the 2 h of reperfusion. Aortic ﬂow, maximum ﬁrst
derivative of developed pressure (dp/dtmax) and left ventricular
developed pressure of reperfusion were found to be signiﬁcantly
improved in NBC treated diabetic rats throughout the reperfusion
time compared to untreated diabetic group. At the end of
reperfusion time (after 120 min of reperfusion), the dp/dtmax
(2020 vs 1691, mm Hg/s), aortic ﬂow (1.5 ml vs 0 ml/min) and
left ventricular developed pressure (80 vs 71 mm of Hg) were found
to be signiﬁcantly improved in the NBC treated diabetic group
compared with the non-treated diabetic control (Fig. 2A–E).
3.3. Effect of NBC on infarct size and cardiomyocyte apoptosis
The infarct size and cardiomyocyte apoptosis was measured in all
the groups after subjecting the hearts to 30 min of global ischemia
and 2 h of reperfusion. Signiﬁcant increase in the infarct size was
observed in the diabetic group as compared to control (37% vs 51%).
NBC treatment has signiﬁcantly reduced the infarct size as compared
to the diabetic group (51% vs 43%) (Fig. 3A). No signiﬁcant difference
was observed between the non-diabetic control and the NBC treated
diabetic group. Similarly, signiﬁcant increase in the cardiomyocyte
apoptosis was observed in the diabetic group as compared to
control. NBC treatment demonstrated signiﬁcant reduction in the
cardiomyocyte apoptosis as compared to the Diabetic group (58 vs
140 counts/100 HPF) (Fig. 3B). The representative pictures of
cardiomyocyte apoptosis by TUNEL assay and the quantitative
measurement of apoptotic cardiomyocytes using Metamorph soft-
ware are shown in Fig. 3C and 3D.
Fig. 6. (A) Represents the p-eNOS and eNOS protein. (B) Represents the p-Akt and Akt protein. (C) Represents the p-AMPK and AMPK expression in the cytosolic fraction. ⁎pb0.05
represents the signiﬁcant difference between control and diabetic group. †pb0.05 represents signiﬁcant difference between diabetic and NBC treated diabetic group.
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the sucrose gradient fractions
Signiﬁcant increase in the caveolin-1 expression was observed in
diabetic group as compared to control. NBC treatment has signiﬁ-
cantly reduced the level of caveolin-1 both in the lipid raft (fractions
4–6) and heavier (fractions 8–12) fractions when compared to diabetic
group (Fig. 4A and B). Reverse pattern was observed in the caveolin-3
expression. Caveolin-3 expression was signiﬁcantly reduced in the
diabetic group as compared to control. NBC treatment has signiﬁ-
cantly increased the expression of caveolin-3 both in lipid raft
(fractions 4–6) and heavier fractions (fractions 8–12) when compared
to diabetic group (Fig. 4C and D). Upon NBC treatment increased
expression of Glut-4 was observed in lipid raft and heavier fractions
when compared to diabetic group. Increased Glut-4 in the lipid raft
fraction in NBC groupmight be due to increased translocation of Glut-
4 following NBC treatment (Fig. 4E and F). As expected, decreased
expression of Glut-4 was observed both in lipid raft as well as in
heavier fractions in the diabetic group compared to non-diabetic
control. However, the ratio of Glut-4 translocation in comparisonwith
lipid raft and heavier fractions between the groups was signiﬁcantly
lower in the diabetic group as compared to control and NBC treated
groups. The control and treated group demonstrated 1:8 fold of Glut-4
translocation into themembrane but in the case of diabetic group only
1:30 fold of Glut-4 translocation to the membrane was observed.
3.5. Effect of NBC on caveolin-1/eNOS and caveolin-3/Glut-4 association
Immunoprecipitation assay was performed to show the associa-
tion of caveolin-1/eNOS and caveolin-3/Glut-4 in the caveolar richlipid raft (fractions 4–6) during diabetes and NBC treatment.
Immunoprecipitation of Cav-1 and immunoblotting with eNOS
clearly demonstrated that in diabetic group eNOS is signiﬁcantly
associated with Cav-1 as shown in Fig. 5A. During NBC treatment we
have observed dissociation of cav-1 and eNOS which might have
resulted in increased phosphorylation of eNOS in the cytosol. In a
similar manner caveolin-3 was immunoprecipitated and reblot with
Glut-4. Decreased association of Glut-4 and caveolin-3 was observed
in diabetic group as compared to control group (Fig. 5B). NBC
treatment documented increased association of Glut-4 and Cav-3 as
compared to DM.
3.6. Effect of NBC on phosphorylation of AMPK, Akt and eNOS in
the cytosol
Phosphorylation of eNOS was found to be decreased in cytosol
of diabetic group and NBC treatment has shown signiﬁcant
increase in the p-eNOS as compared to diabetic group (Fig. 6A).
Decreased eNOS phosphorylation in diabetic group might be due
to increased cav-1/eNOS interaction or association which possibly
made eNOS unavailable for its activation. Similarly, phosphoryla-
tion of Akt was found to be decreased in cytosol of diabetic
group and NBC treatment has shown signiﬁcant increase in the
p-Akt as compared to diabetic group (Fig. 6B). The phosphoryla-
tion of AMPK was also found to be reduced in diabetic group as
compared to non-diabetic control. Upon NBC treatment phos-
phorylation of AMPK signiﬁcantly increased as compared to the
non-treated diabetic control (Fig. 6C). The non phosphorylated
forms of these proteins were used as their corresponding loading
controls.
Fig. 7. (A) Represents the rat cardiac parafﬁn sections labeled with immunoﬂuorescence and visualized using confocal microscopy (400×). I, II and III represent the green ﬂuorescence
labeled caveolin-3. IV, V and VI represent red ﬂuorescence labeled Glut-4. VII, VIII and IX represent the merged picturewhich clearly shows the co-localization of caveolin-3 and Glut-
4. White arrows denote the caveolin-3 and Glut-4 association. I, IV and VII represent control group, II, V and VIII represent Diabetic group and III, VI and IX represent Diabetic+NBC
group. (B) Represents the rat cardiac parafﬁn sections labeled with immunoﬂuorescence and visualized using confocal microscopy (400×). I, II and III represent the red ﬂuorescence
labeled caveolin-1. IV, V and VI green ﬂuorescence labeled eNOS. VII, VIII and IX represent the merged picture which clearly shows the co-localization of caveolin-1 and eNOS. White
arrows denote the caveolin-1 and eNOS association. I, IV and VII represent control group, II, V and VIII represent Diabetic group and III, VI and IX represent Diabetic+NBC group.
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Cav-3/Glut-4 association
Western blot analysis was also further conﬁrmed by immuno-
histochemical analysis. The immunohistochemical analysis docu-
mented signiﬁcant decrease in the expression of Cav-3 and increase
in the Cav-1 in the membrane of diabetic group as compared to
control [Fig. 7A (II) and B (II)]. As expected, on treatment with NBC
converse results were obtained as compared to diabetic group [Fig.
7A (III) and B (III). Moreover, signiﬁcant association of Cav-1/eNOS
in the membrane was observed in the diabetic group as compared
to control [Fig. 7B (VIII)]. On NBC treatment Cav-1/eNOS association
was found to be decreased as compared to the diabetic group [Fig.
7B (IX)]. DM has shown decreased Glut-4 translocation to the
membrane and association with caveolin-3 as compared to control
[Fig. 7A (VIII)]. On NBC treatment increased Glut-4 translocation
and association with caveolin-3 was observed as compared to
diabetic group [Fig. 7A (IX)].
4. Discussion
In the present study we report the effect of Niacin-bound
Chromium (NBC) in regulation of Glut-4 translocation in STZ-induced
diabetic rats. The result of the present study clearly demonstrates NBC
mediated Glut-4 expression and translocation might be mediated by
modulating the Cav-1 and Cav-3 status in diabetic myocardium after
IR injury. Dissociation of Cav-1/eNOS interaction, increased transloca-
tion of Glut-4 and its association with caveolin-3 with increased
phosphorylation of AMPK, Akt and eNOS was observed upon NBC
treatment. However, at present we don't know whether there is any
alteration in glucose uptake or metabolism.
Our results suggest that NBC mediated Glut-4 translocation may
be through the activation of the AMPK/Akt/eNOS signaling cascade,
which is further regulated by the Cav-1 and Cav-3 status.Signiﬁcant reduction in the phosphorylation of AMPK was observed
in diabetic group as compared to non-diabetic control. The key role
of AMPK in the heart is the regulation of energy metabolism [32].
Large amounts of ATP are necessary to sustain contractile function
and basal metabolism in a normal heart and this is primarily
generated by mitochondrial oxidative metabolism, with a small
amount derived from glycolysis [32]. Cardiac function is also
dependent on the production of intracellular ATP derived from
glucose metabolism [33]. NBC treatment increased the phosphor-
ylation of AMPK as compared to the non-treated diabetic control.
This signiﬁcant increase in the levels of p-AMPK correlate with the
improvement of the cardiac functions during reperfusion in the
NBC treated group as compared to the non-treated diabetic group.
AMP-activated protein kinase functions as a metabolic master
switch which senses and regulates the cellular energy status in
various cells [24]. AMPK has also been reported to induce Glut-4
upregulation and translocation to the membrane after ischemic
preconditioning [11]. Moreover, enhanced Glut-4 translocation and
increased glucose uptake by 5-aminoimidazole-4-carboxy-amide-1-
β-D-ribofuransoside (AICAR) was found to be mediated by activa-
tion of AMPK [26]. We have observed decreased Glut-4 expression
in the membrane fractions of the diabetic group as compared to
the normal control. However, NBC treatment increased the
expression of Glut-4 in the membrane fractions as compared to
the non-treated diabetic control animals. This observation agrees
with previous reports that AMPK activates the expression and
translocation of Glut-4 [27]. Glut-4 is the major insulin-responsive
glucose transporter that clears glucose from the blood. In the
absence of insulin, Glut-4 is sequestered into specialized storage
vesicles that remain within the cell [9]. AMPK is also known to
phosphorylate eNOS at Ser 1177 rendering it active [23]. We have
documented decreased expression of p-eNOS in the diabetic group
as compared to the normal control. Upon NBC treatment the
expression of p-eNOS signiﬁcantly increased in the treated group
47S.V. Penumathsa et al. / Biochimica et Biophysica Acta 1792 (2009) 39–48as compared to the non-treated diabetic control. eNOS is the source of
NO and is important in regulation of blood pressure, vascular
remodeling, vasodilation, angiogenesis and wound healing [24]. The
vasodilatory function of eNOS might explain the improved aortic ﬂow
in the NBC treated group as compared to the non-treated diabetic
control. eNOS is also known to be regulated by Akt/PKB [34].
Akt/PKB is a critical central signaling node, downstream of many
growth factors. Akt substrates contribute to the diverse cellular roles
including cell survival, growth, proliferation, angiogenesis, metabo-
lism, and migration [35]. It has been reported that Akt enhances the
survival of cells by blocking the function of proapoptotic proteins and
processes [36]. Phosphorylation of Akt has also been known to play a
very important role in facilitating growth factor-mediated cell survival
and in blocking apoptotic cell death [37]. Reports have also shown that
phosphorylation and activation of Akt play an essential role in Glut-4
translocation as well by being involved in docking and/or fusion of
Glut-4 vesicles with the cell surface [38,39]. In our present study we
have also observed signiﬁcantly increased p-Akt in the NBC treated
group as compared to the non-treated diabetic control. However, p-
Akt was signiﬁcantly decreased in the diabetic group as compared to
the non-diabetic control. This activation of p-Akt explains the
activation of the survival pathway in the NBC treated group and
hence the signiﬁcant decrease in the number apoptotic cardiomyo-
cytes and improved functions as compared to the diabetic control after
ischemia reperfusion.
Our previous results have shown that eNOS activity is also known
to be regulated by differential regulation of the Cav-1 [10]. Endothelial
nitric oxide synthase (eNOS) is one of the many proteins tethered to
Cav-1. Bucci et al. have reported the regulation of eNOS activity by
Cav-1 [40,41]. The expression of Cav-1 in the endothelial cells seems to
be directly linked to the inhibition of NO synthesis [42]. In the present
study our results demonstrate signiﬁcant increase in the expression of
Cav-1 in the diabetic group while NBC treatment signiﬁcantly reduced
the expression of Cav-1 as compared to the non-treated diabetic
control. In addition, McCarty has demonstrated that nitric oxide
deﬁciency, the crucial factor for pathogenesis during diabetes can be
prevented by antioxidants, essential fatty acids and chromium
supplementation [43]. Furthermore, immunohistochemical and
immuno-precipitation analysis for Cav-1/eNOS association has also
shown signiﬁcant increase in the Cav-1/eNOS association in the
diabetic group in the membrane as compared to the non-diabetic
control. As expected, NBC treatment disrupted the Cav-1/eNOS
association releasing eNOS, thus increasing it's availability as a target
substrate for phosphorylation for both activated AMPK and Akt. This
explains our observation of increased p-eNOS in the NBC treated
group and how its activation is inversely proportional to the
expression of Cav-1.
On the other hand, Cav-3 expression was signiﬁcantly decreased
in the diabetic group in the caveolar lipid raft fractions when
compared to the non-diabetic control. Caveolin 3 knockout mice
(Cav3−/−) have been reported to show increased adiposity and insulin
resistance [19]. NBC treatment signiﬁcantly increased the expression
of Cav-3 in lipid raft fractions in the treatment group as compared to
the non-treated diabetic control. Immunohistochemical analysis has
shown increased association of Glut-4 and Cav-3 in the NBC treated
group as compared to the non-treated diabetic control which was
further validated by immuno-precipitation. However, this association
was signiﬁcantly reduced in the diabetic group as compared to the
non-diabetic control. Earlier reports have shown that Glut-4
translocates to the caveolin-enriched membrane domains after
insulin stimulation in adipocytes [44,45]. Karlsson et al. have
demonstrated morphologically and biochemically that, in the plasma
membrane of adipocytes Glut-4 is localized in caveolae resulting in
glucose uptake [46]. Moreover, disruption of caveolae was shown to
make adipose cells insulin resistant [47]. These reports suggest that
caveolin signaling plays an important role in Glut-4 translocation andglucose uptake. Increased expression of Cav-3 along with Glut-4 and
their association in NBC treated diabetic myocardium supports the
notion that Glut-4 translocation occurs to the caveolae in the
membrane and Cav-3 tethers Glut-4 to the cell surface lipid raft
domains when stimulated.
To summarize, NBC mediated Glut-4 translocation may be
mediated by 1) disruption of the Cav-1/eNOS interaction resulting in
increased phosphorylation of eNOS 2) increase in the activation of
AMPK and Akt 3) increase in the association of Glut-4 and Cav-3 in the
membrane. The reduction in infarct size and cardiomyocyte apoptosis
in NBC treated diabetic myocardium might be due to the activation of
Akt and eNOS. However, further investigations are necessary to
conﬁrm the protective role of NBC in caveolin signaling during
ischemia reperfusion in diabetic animals.
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